Cas:67659-37-4 (S)-1,1-Diphenylpropan-2-amine manufacturer & supplier

We serve Chemical Name:(S)-1,1-Diphenylpropan-2-amine CAS:67659-37-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(S)-1,1-Diphenylpropan-2-amine

Chemical Name:(S)-1,1-Diphenylpropan-2-amine
CAS.NO:67659-37-4
Synonyms:MFCD03093552;(2S)-1,1-diphenylpropan-2-amine
Molecular Formula:C15H17N
Molecular Weight:211.30200
HS Code:2921499090

Physical and Chemical Properties:
Melting point:78-82ºC(lit.)
Boiling point:324.2ºC at 760 mmHg
Density:1.022 g/cm3
Index of Refraction:
PSA:26.02000
Exact Mass:211.13600
LogP:3.86600

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like MFCD03093552 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2S)-1,1-diphenylpropan-2-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD03093552 Use and application,(2S)-1,1-diphenylpropan-2-amine technical grade,usp/ep/jp grade.


Related News: Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia. (S)-1,1-Diphenylpropan-2-amine manufacturer Taiwan previously participated as an observer at the World Health Assembly, the W.H.O.��s governing body. (S)-1,1-Diphenylpropan-2-amine supplier Taiwan previously participated as an observer at the World Health Assembly, the W.H.O.��s governing body. (S)-1,1-Diphenylpropan-2-amine vendor Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia. (S)-1,1-Diphenylpropan-2-amine factory AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment.